SCHEMBL4714259

SCHEMBL4714259

O=C(c1cccc(N2Cc3cccc(Cl)c3C2=O)c1)N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 1/20 0.60
LMNA P02545 3/20 0.60
TSHR P16473 2/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MAPK1 P28482 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
ADRB2 P07550 1/20 0.52
ALDH1A1 P00352 4/20 0.52
KDM4E B2RXH2 3/20 0.52
PARP1 P09874 1/20 0.52
NPC1 O15118 1/20 0.50
HSD11B1 P28845 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715714 0.92 BDKRB1 (0.57) BDKRB1LMNATSHRMEN1KMT2A
SCHEMBL4712656 0.85 BDKRB1 (0.59) BDKRB1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL4714797 0.85 BDKRB1 (0.58) BDKRB1LMNATSHRMEN1KMT2A
SCHEMBL4713885 0.84 BDKRB1 (0.57) BDKRB1LMNATSHRMEN1KMT2A
SCHEMBL4716862 0.84 BDKRB1 (0.64) BDKRB1LMNATSHRMEN1KMT2A
SCHEMBL4760693 0.83 BDKRB1 (0.66) BDKRB1LMNATSHRSMN1; SMN2MAPK1
SCHEMBL4713388 0.83 BDKRB1 (0.56) BDKRB1MAPK1L3MBTL1ADRB2ALDH1A1
SCHEMBL4717372 0.82 BDKRB1 (0.56) BDKRB1SMN1; SMN2ADRB2ALDH1A1PARP1
SCHEMBL4716396 0.82 BDKRB1 (0.61) BDKRB1MEN1KMT2APARP1
SCHEMBL4711496 0.81 BDKRB1 (0.65) BDKRB1LMNATSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US claimed
EP-1877401-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM Elan Pharmaceuticals Inc. (US) 2008-01-16 EP disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
WO-2006113140-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM ELAN PHARMACEUTICALS, INC. (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism BDKRB1, BDKRB2, NPBWR1 BDKRB1 1/4885LMNA 1762/4885TSHR 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.